MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "MAO-B inhibitors"

  • 2018 International Congress

    Use of safinamide: A clinical practice review of 2 year experience

    C. Borrue-Fernandez (San Sebastian Reyes, Spain)

    Objective: Review the clinical use, efectivity and side efects in a population based cohort. Background: Safinamide is an oral, once a day adjunctive therapy for…
  • 2018 International Congress

    Anti-glutamatergic effect of safinamide in Parkinson’s Disease: A TMS study

    A. Guerra, A. Suppa, V. D'Onofrio, F. Di Stasio, F. Asci, G. Fabbrini, A. Berardelli (Rome, Italy)

    Objective: To test the effect of safinamide, at the doses of 50 and 100 mg/day, on primary motor cortex (M1) excitability and glutamatergic neurotransmission in…
  • 2018 International Congress

    Safinamide in Parkinson’s disease

    G. Martí-Andrés, R. Jiménez-Bolaños, J. Arbelo-González, J. Pagonabarraga-Mora, C. Duran-Herrera, M. Carmona-Abellán, R. Luquin-Puido (Pamplona, Spain)

    Objective: To evaluate clinical effects, safety and tolerability of safinamide add-on levodopa in Parkinson’s disease (PD) patients. Background: Safinamide is a recently approved adjunctive treatment…
  • 2018 International Congress

    Efficacy and safety of Rasagiline in treatment of gait disturbances in dementia with Lewy bodies

    A. Chimagomedova, O. Levin, M. Anikina, I. Ayzenberg (Moscow, Russian Federation)

    Objective: We aimed to investigate the efficacy and safety of rasagiline in addition to levodopa in patients with dementia with Lewy bodies (DLB). Background: Management…
  • 2018 International Congress

    Safinamide add-on therapy increases ON time without dyskinesia in fluctuating Parkinson’s Disease (PD) patients with moderate to severe dyskinesia

    V. Tubazio, C. Cattaneo, E. Bonizzoni, C. Keywood (Bresso (Milan), Italy)

    Objective: This post-hoc analysis examined safinamide efficacy for providing dyskinesia-free ON time in LID patients. Background: Safinamide has both dopaminergic and glutamate modulating activity. The…
  • 2018 International Congress

    Evaluation of the interaction between safinamide and opicapone in Parkinson’s disease patients with fluctuations

    J. Garcia-Caldentey, MA. Prats-Sedano, I. Legarda-Ramirez, E. Estelrich-Peyret, B. Vives-Pastor, PJ. Garcia (Palma de Mallorca, Spain)

    Objective: To describe and to evaluate a Balearic ongoing Parkinson's disease (PD) Project to evaluate the efficacy and tolerance of the interaction between safinamide and…
  • 2017 International Congress

    The SYNAPSES study  (StudY to observe SafiNAmide in clinical Practice during the firSt post-commErcialization phaSe): methodology and results from the European feasibility survey

    G. Camattari, G. Abbruzzese, W. Jost, J. Kulisevsky, V. Tubazio, L. Simoni, The SYNAPSES investigators (Bresso, Italy)

    Objective: Here we present the design of a Drug Utilization Study of safinamide in the first post-commercialization phase and report results of the study feasibility…
  • 2017 International Congress

    Safinamide improves both motor and non-motor symptoms in fluctuating Parkinson’s Disease patients.

    C. Cattaneo (Bresso (Milan), Italy)

    Objective: To investigate the efficacy of safinamide, compared to placebo, as add-on therapy to stable doses of levodopa, on both motor and non-motor symptoms in…
  • 2016 International Congress

    Long-term efficacy of safinamide on mood in Parkinsonian patients with fluctuations

    C. Cattaneo, E. Mueller, M. Sardina (Bresso, Italy)

    Objective: The present post-hoc analysis of the results of two pivotal trials (016 and 018) investigated the effects of safinamide 100 mg/day on mood in…
  • 2016 International Congress

    Implications of direct and indirect costs in health-related quality of life in Parkinson’s disease: A cross-sectional study in Mexico

    M. Rodríguez-Violante, A. Jorge de Saráchaga, A. Cervantes-Arriaga, H. Soto-Molina, M. Márquez-Cruz (Mexico City, Mexico)

    Objective: To evaluate the association of direct and indirect costs of Parkinson's disease (PD) and health-related quality of life (HRQoL) in a Mexican population. Background:…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley